In this podcast episode, listen to myeloma experts Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer audience questions from a live CCO Webinar on available and emerging therapeutic strategies for patients with early and late relapsed/refractory multiple myeloma.
Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on new agents and approaches for relapsed/refractory multiple myeloma, including strategies for early relapse, BCMA-targeted treatments for late relapse, and novel targeted agents.
Download these slides to review expert insights on available treatments for patients with early relapsed, refractory MM
Download these slides to review expert insights on available treatments for patients with late relapsed, refractory MM.
Download these slides to review expert insights on novel agents with new targets for patients with relapsed, refractory MM.
How will you incorporate belantamab mafodotin into your clinical practice for patients with relapsed/refractory multiple myeloma? Here are my thoughts.
Read my thoughts on treating patients with multiple myeloma who experience biochemical relapse.